slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 901-930
Pages 1,418
Rows per page 30
Beat
901-930 of 42,534
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
18
The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
19
The slide details a specific licensing deal, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
20
The slide uses a three-column layout to explain the scientific basis and benefits of the drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
21
Includes IC50 value and IFN-y fold increase data from patient samples.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
22
The slide uses a three-column layout to highlight the core benefits of the product.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
23
Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
24
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
25
The slide maps the viral genome to specific drug targets and highlights partnerships with X-Chem and Proteros.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
26
The slide highlights key therapeutic advantages of the candidate drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
27
The slide uses a table to present a timeline of clinical milestones.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
28
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
24
The slide uses a block-based organizational structure to illustrate the separation of core business units from those designated for wind-down or risk reduction.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
25
The slide uses a 4-row process/strategy framework to categorize business units. The charts show the reduction in RWA and Leverage Exposure from 2020 to 3Q22.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
26
The slide uses a stacked bar chart to illustrate the shift in RWA composition. The 'New Credit Suisse' grouping is a key strategic highlight.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
27
The slide uses a stacked bar chart to illustrate the strategic pivot of Credit Suisse's business model.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
28
The slide uses a waterfall-style chart to show the impact of capital raises on the CET1 ratio.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
29
The slide combines a summary table of capital raise details with a horizontal timeline of execution steps.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
30
Slide 30 of a presentation deck.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
31
The slide uses a process-oriented layout to define the operational framework for a business unit carve-out.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
32
The slide compares RWA (35bn) and Leverage Exposure (132bn) across five asset categories.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
33
The slide uses a process-style arrow to connect the progression charts to the expected outcomes by 2025.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
34
The chart uses a waterfall bridge structure to show capital movements.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
35
The slide uses a bridge/waterfall logic to show how strategic actions reduced the net impact of Basel III reforms from ~35-40bn to ~15bn.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
36
The slide uses a waterfall-style logic to show the reduction from 2022 guidance to 2025 target.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction2 hits
37
Includes specific targets like 2,700 FTE reduction and 50% reduction in consultancy spend.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction2 hits
38
The slide breaks down costs into specific time periods (3Q22-2024) and highlights a CET1 ratio impact.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
39
The chart uses a break in the axis to handle the large negative value of 9M22 reported RoTE.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
40
The slide uses a side-by-side layout connecting strategic actions to quantitative financial outcomes.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)2 hits
19
Includes a progress bar at the bottom indicating the current stage is Phase 2b.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits